Aller au contenu principal
2026 conference-abstract

EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

0Citations signalées, ce qui n’est pas une note de qualité
15Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : us, pr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

e19003 Background: Epcoritamab, a CD3×CD20 bispecific antibody approved for R/R DLBCL, is administered SC with inpatient monitoring for 24 h after the first full dose (FFD). Previous report from NHL-6 (NCT05451810) demonstrated feasibility of outpatient dosing and monitoring of epcoritamab in 2L+ DLBCL after FFD, with 92% of patients (pts) monitored outpatient after FFD (Vaidya SOHO 2025 Abstract ABCL-1224). Here we present longer follow-up data. Methods: Pts aged ≥18 y with R/R DLBCL, ECOG PS 0–2, who received ≥1 prior line of therapy (LOT), including immunochemotherapy with anti-CD20 antibody, were enrolled in academic and community centers of US and Puerto Rico. Pts received epcoritamab in 28-day (D) cycles (C): 0.16-mg and 0.8-mg C1 step-up doses, 48-mg full dose C1D15 onward (C1–3, QW; C4–9, Q2W; C≥10, Q4W). Safety education materials and mandatory cytokine release syndrome (CRS) prophylaxes were given in C1. Primary endpoints were grade ≥3 CRS, immune effector cell–associated neurotoxicity syndrome (ICANS), and neurologic events. Secondary endpoints were efficacy and safety. Results: At the 11 Nov 2025 cutoff, 92 pts received ≥1 dose of epcoritamab and the baseline characteristics have been reported previously (Vaidya SOHO 2025 Abstract ABCL-1224). The median number of treatment cycles was 6 (range 1–35). At 17.3-mo median follow-up (95% CI 15.4–18.9), all pts experienced ≥1 treatment-emergent adverse event (TEAE), with 22.8% leading to treatment discontinuation (5.4% DLBCL disease progression reported as TEAE). Grade 3–4 TEAEs occurred in 81.5%, Grade 5 TEAEs in 17.4% of pts (7.6% DLBCL disease progression, 5.4% infections [3.3% COVID-19]), and serious adverse events in 65.2%. Infections and infestations were reported in 68.5% of pts, including 26.1% that were serious. The incidence and severity of CRS and ICANS were consistent with prior reports. With extended follow-up, the overall response rate (ORR) and time to response remained consistent with earlier analyses. Higher complete response rates (CRR) were observed with epcoritamab in 2L vs overall (Table). Median duration of response (mDOR) was 25.8 mo and median duration of complete response (mDOCR) was not reached (NR). Median progression-free survival (mPFS) was 7.9 mo. Median overall survival (mOS) was 27.2 mo. Conclusions: With longer follow-up, the overall safety profile remained consistent with previous report, with no new safety signals identified. Responses observed with epcoritamab were durable and mOS was 27.2 mo. Higher CRR observed in the 2L group suggested enhanced benefit with using epcoritamab in earlier LOTs. Clinical trial information: NCT05451810 . EPCORE NHL-6 efficacy outcomes. Outcome, 95% CI 2L (n=42) Overall (n=92) ORR % 66.7, 50.5–80.4 64.1, 53.5–73.9 CRR % 57.1, 41.0–72.3 48.9, 38.3–59.6 mPFS mo 11.4, 5.5–NR 7.9, 4.2–NR mDOR mo NR, 8.7–NR 25.8, 25.8–NR mDOCR mo NR, NR–NR NR, 24.8–NR mOS mo NR, NR–NR 27.2, 13.4–NR

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Date Crossref
01/06/2026
Éditeur
American Society of Clinical Oncology (ASCO)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Rocky Mountain Cancer Centers pays non établi dans la notice
    Établissement de santé
  • Center for Cancer and Blood Disorders pays non établi dans la notice
    Structure de recherche
  • Auxilio Mutuo Hospital pays non établi dans la notice
    Établissement de santé
  • Atrium Health Wake Forest Baptist pays non établi dans la notice
    Établissement de santé
  • Virginia Cancer Specialists pays non établi dans la notice
    Établissement de santé
  • Penn State Milton S. Hershey Medical Center pays non établi dans la notice
    Établissement de santé
  • Massachusetts General Hospital pays non établi dans la notice
    Établissement de santé
  • Oklahoma State University Oklahoma City pays non établi dans la notice
    Université ou école supérieure
  • University of Oklahoma pays non établi dans la notice
    Université ou école supérieure
  • Moffitt Cancer Center pays non établi dans la notice
    Établissement de santé
  • Memorial Healthcare System pays non établi dans la notice
    Établissement de santé
  • Icahn School of Medicine at Mount Sinai pays non établi dans la notice
    Université ou école supérieure

Rocky Mountain Cancer Centers, Center for Cancer and Blood Disorders et Auxilio Mutuo Hospital, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

CAR-T cell therapy researchLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.